Humanigen, Inc. announced that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-launched Managed Access Program (“LenzMAP™”). Clinigen Group plc (“Clinigen”) is implementing the program. Lenzilumab is an investigational product and is not currently authorized or approved in any country.

Clinigen is an expert in delivering specialty therapies on a named-patient basis in the UK and Europe. Lenzilumab is available via LenzMAP in the following 17 countries: Austria, Bulgaria, Croatia, Cyprus, Denmark, Estonia, France, Greece, Ireland, Lithuania, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, and United Kingdom. LenzMAP will enable access to lenzilumab on a case-by-case basis for hospitalized patients with COVID-19 for whom the treating physician deems there are no suitable alternatives and where regulations allow.

Clinigen will manage key elements of LenzMAP, including regulatory oversight, reimbursement, logistics, and access management.